N/A N=82

TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions

Peripheral Arterial Disease

Bottom Line

View on ClinicalTrials.gov: NCT03306199 ↗

Enrolled (actual)

Serious AEs

23.9%

Results posted

Apr 2019

Primary outcome: Primary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Laser Atherectomy (Device)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Spectranetics Corporation
Primary completion: Jun 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Free From Target Lesion Revascularization (TLR)	52	—

Summary

A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).

Eligibility Criteria

Inclusion Criteria

All patients treated for femoropopliteal de novo/restenotic lesions or in-stent restenosis using Turbo Power laser atherectomy plus drug coated balloon angioplasty

Exclusion Criteria

Any incomplete data on procedural approach and treatment

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03306199). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.